Overview

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Shire
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Ecallantide